
Following on from the popularity of our previous free webinar sessions, Pharmafocus is once again partnering with PrimeVigilance to bring you an overview of the EudraVigilance changes and their impact on MAHs.
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader

